Page 9 - Iontech News Today

BioNTech’s alliance with DualityBio gives it two antibody drug conjugate (ADC) candidates, the most advanced of which is in mid-stage clinical development for solid tumors. It addresses the same target as a potential blockbuster AstraZeneca drug.

Consolidated Financial Statements BioNTech SE, Mainz as of December 31, 2022 Consolidated Statements of Profit or Loss Years ended ... | March 29, 2023

The company is expecting this drop in demand to accelerate through 2023.

MAINZ, Germany, March 28, 2023 -- BioNTech SE  today announced that it has entered into a new share repurchase program , pursuant to which the Company may purchase American Depositary Shares,... | March 28, 2023

Anticipating demand, private clinics charging up to HK$2,800 per shot have advertised on social media since January.

By Cecilia Butini BioNTech SE on Monday posted lower revenue and profit for the fourth quarter of 2022, and said it expects a fall in revenue from its Covid-19 vaccines in the current year. ... | March 27, 2023

BioNTech expects revenue from its COVID-19 vaccines to hit €5bn (US$5.3bn) in 2023, which would be lower than market expectations.

Like Moderna and Pfizer, the biotech company is turning its covid windfall to the quest for new cancer treatments

BioNTech and OncoC4 have announced a worldwide license and collaboration agreement to develop and commercialize OncoC4’s next-generation anti-CTLA-4 monoclonal antibody candidate, ONC-392, as monotherapy or combination therapy in various cancer indications.

A USA FDA-approved skin care laser, Picocare 250 Majesty is from Wontech, South Korea, with the aim to redefine the contours of skin laser care and aesthetics in India, uncovering the youthful glow hidden by ageing and skin-related problems.Adding to the expansive array of advanced technology available at DAC http www.doctorsaestheticscentre.com , Picocare 250 Majesty is set to resolve a variety of skin-related procedures with maximum efficiency.